| Home | E-Submission | Sitemap | Contact Us |  
top_img
J Korean Cancer Assoc > Volume 26(1); 1994 > Article
Journal of the Korean Cancer Association 1994;26(1): 136-144.
소아 급성골수성백혈병 환자의 화학요법에 따른 호중구 감소에 대한 Filgrastim ( rhG - CSF ) 의 효과
신희영, 박경덕, 하성훈, 구흥회, 안효섭
Effect of Filgrastim ( rhG - CSF ) on Chemotherapy Induced Neutropenia in Pediatric Acute Myelogenous Leukemia Patients
Hee Young Shin, Hee Young Shin, Seong Hoon Hah, Hong Hoe Koo, Hyo Seop Ahn
ABSTRACT
To determine the safety and efficacy of rhG-CSF on chemotherapy induced neutropenia in pediatric AML patients, we conducted a prospective controlled study in 17 patiens with AML at Seoul National University Childrens Hospital from July, 1993 to January, 1994. High dose cytosine arabinoside(Ara-C, 3gm/m for four times every 12 hours) with L-asparaginase 6,000 u/m) were given to 13 patients as Group I control and after the recovery of WBC, same chemo- therapy followed by G-CSF(50 ug/m for 10 days) were given as Group I study. In Group II study, high dose Ara-C(3gm/m(2) for 8 times every 12 hours) were given to 11 patients with AML followed by G-CSF(150 ug/m for 10 days). Recovery of the absolute neutrophil counts to more than 1,000/mm' was significantly faster in the G-CSF group than in the control group(P< 0.01) and the absolute neutrophil counts on day 14 of chemotherapy was significantly higher in G-CSF group(P<0.01). The toxicity of G-CSF was minimal and there was no evidence of accel- erated growth of leukemic blasts during the G-CSF treatment. In conclusion, Filgrastim(rhG- CSF) promotes the recovery of neutrophils and shortens the duration of neutropenia induced by the chemotherapy in pediatric acute myelogenous leukemia.
Key words: Filgrastim, G-CSF, Childhood, AML, Neutropenia, Chemotherapy
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association. All rights reserved.                 Developed in M2PI